OVSTAR TIL Trial (OVarian Cancer Co-STimulatory Antigen Receptor TIL Trial)
Status:
Withdrawn
Trial end date:
2025-07-31
Target enrollment:
Participant gender:
Summary
An open label, multi-centre Phase 1/2a study of modified and unmodified autologous Tumour
Infiltrating Lymphocytes (TIL) in patients with platinum-resistant ovarian cancer. The
purpose of this phase I/II study is to evaluate the feasibility and safety of both standard
unmodified TIL (UTIL-01) and TIL engineered to express the co-stimulatory receptor CoStAR
(CoTIL-01) in platinum resistant ovarian cancer.